Drug Firm Dr Reddy'S Laboratories On Thursday Said It Has Launched Generic Naloxone Hydrochloride Injection, Indicated For Complete Or Partial Reversal Of Opioid Depression, In The Us Market. The Company Has Launched Naloxone Hydrochloride Injection Usp, 2 Mg/2 Ml (1 Mg/Ml) Single-Dose Prefilled Syringe After The Approval From The United States Food And Drug Administration (Usfda), Dr Reddy'S Said In A Statement.The Product Is A Generic Version Of Adapt Pharma Operations Ltd'S Narcan Injection, It Added."We Are Pleased To Bring Our Second Product To Market That Has Been Designated As A Competitive Generic Therapy (Cgt) By The Usfda," Dr Reddy'S Laboratories North America Generics Ceo Marc Kikuchi Said.With A Cgt Designation, The Company Has 180-Day Cgt Exclusivity To Market This Product, He Added.According To Iqvia Health Data, Naloxone Hydrochloride Injection Usp, 2 Mg/2 Ml (1 Mg/Ml) Had Us Sales Of Around Usd 31 Million (About Rs 230 Crore) Moving Annual Total For The Most Recent Twelve Months Ended In January 2020.Shares Of Dr Reddy'S Laboratories On Thursday Closed 1.69 Per Cent Lower At Rs 2,622.75 On The Bse.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!